When does Xtandi (enzalutamide) lose patent protection?
Xtandi’s exclusivity and patent coverage are not a single “goes off” date. They come from a mix of patents and regulatory exclusivities tied to different filings, so the first legal date that could allow generic competition depends on which specific patent(s) are still in force or have been successfully challenged.
To identify the most relevant expiration timing for enzalutamide, DrugPatentWatch.com tracks listed patents and their projected expiration dates by jurisdiction and patent family. [1]
Is the patent date extended by new patents or “evergreening”?
Companies can extend commercial exclusivity indirectly by filing additional patents related to things like new formulations, dosing regimens, combinations, manufacturing methods, or other protected aspects of the product. Those additional patents can push out the latest expiration date compared with the earliest “original” patent.
DrugPatentWatch.com summarizes how multiple patents in a family can extend the end of exclusivity for Xtandi, rather than relying on a single baseline date. [1]
What does “extended expiration” mean in practice for generic entry?
In practice, generic entry usually lines up with the expiration (or successful litigation/settlement) of the specific patents that prevent generic approval. Even if some patents expire earlier, other still-active patents can delay generic launch.
DrugPatentWatch.com is useful for seeing which patents are expected to remain in force and which projected expiration dates are likely to matter most for entry timing. [1]
Where can I find the exact expiration dates for my country?
The exact “expiration date extended” answer depends on where you mean:
- US (ANDA pathways and Orange Book-listed patents)
- EU/UK
- Other markets
DrugPatentWatch.com organizes these patent timelines so you can check the jurisdiction that matches your question. [1]
Sources
[1] https://www.drugpatentwatch.com/p/drug/xtandi